TNFRSF17 and plasma cell myeloma: We previously reported a phase I study of a novel fully human BCMA-targeting CAR (CT103A) in 18 patients with relapsed/refractory multiple myeloma (http://www.chictr.org.cn, Number, ChiCTR1800018137) (Wang et al., 2021).